The Economic Conundrum for Antibacterial Drugs

Sustainable Discovery and Development of Antibiotics — Is a Nonprofit Approach the Future?

(2019) Travis B. Nielsen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data

(2019) Cornelius J Clancy et al.   Open Forum Infectious Diseases

Estimating the Size of the U.S. Market for New Antibiotics with Activity against Carbapenem-Resistant Enterobacteriaceae

(2019) Cornelius J. Clancy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

OUP accepted manuscript

(2018)   CLINICAL INFECTIOUS DISEASES

Pseudomonas aeruginosa urinary tract infections in hospitalized patients: Mortality and prognostic factors

(2017) Jose Luis Lamas Ferreiro et al.   PLoS One

Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure

(2016) Deanna J. Buehrle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Emerging Resistance, New Antimicrobial Agents  …  but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape

(2016) R. M. Humphries et al.   CLINICAL INFECTIOUS DISEASES

Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality

(2016) Kevin Outterson et al.   PLOS MEDICINE